Applications published 7 January 2009

• Use of galactose C-glycoside derivatives as protective agent and/or T lymphocyte activator
L’Oreal 2010137*

• Polyesteramide platform for site specific drug delivery
Abbott Cardiovascular Systems 2010142*

• Stabilised ophthalmic compsns comprising oxidatively unstable components
Johnson & Johnson Vision Care 2010143*

• Modification of percutaneous absorption of topically active materials
Croda 2010145*

• Non-covalent complexes of bioactive agents with starch for oral delivery
Technion Research and Development Foundation 2010147*

• Compsn including at least one aqueous phase and at least one fatty phase including ivermectin
Galderma 2010148*

• Nanostructured compsns having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties
Novavax 2010149*

• Stable emulsion formulations
Amgen 2010150*

• Treatment of triple receptor negative breast cancer
MediGene 2010151*

• Magnetic nanoparticles compsns and uses thereof
Nanobiotix 2010152*

• Drug microparticles
Teva Pharmaceutical Industries 2010153*

• Mask-tasting solid preparation of pioglitazone
Takeda Pharmaceutical 2010154*

• Glucagon-like peptide 1 (GLP-1) pharmaceutical formulations
MannKind 2010155*

• Stabilised compsns containing alkaline labile drugs
Auxilium International Holdings 2010156*

• Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion
Ethypharm 2010157*

• Controlled release formulations comprising uncoated discrete uni(s) and am extended release matrix
Alphapharm 2010158*

• Fast release paracetamol tablets
SmithKline Beecham 2010159*

• Oral dosage formulations and methods of preparing the same
Actavis Group 2010161*

• Drug delivery compsn
Odidi, Isa; Odidi, Amina 2010162*

• Co-crystals of calixarenes and biologically active molecules
Centre National de la Recherche Scientifique; Universite Claude Bernard de Lyon; Institute of Physical Chemistry — Polish Academy of Sciences 2010163*

• S-nitrosothiols containing compsns and the use of such compsns for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compsns
Universidade Estudual de Campinas-Unicamp; Universidade De Sao Paulo-USP 2010164*

• Abnormal cannabidiols as agents for lowering intraocular pressure
Allergan 2010165*

• Organic thiophosphate antiretroviral agents
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services; Lovelace Respiratory Research Institute 2010166*

• Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
Actelion Pharmaceuticals 2010167*

• Histone deacetylase inhibitors
The President and Fellows of Harvard College 2010168*

• The genetic risk assessment in heart failure: impact of the genetic variation of G-protein beta 2 subunit polymorphism
Nitromed; University of Pittsburgh of the Commonwealth System of Higher Education 2010169*

• Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
Novartis; Novartis Pharma 2010170*

• Inhibitors of PAI-1 for treatment of muscular conditions
Wyeth 2010171*

• Indoles and benzimidazole as modulators of the histamine H4 receptor
Janssen Pharmaceutica 2010172*

• Compounds for treating pulmonary hypertension
Bayer HealthCare 2010173*

• Pharmaceutical modulation of positive AMPA receptor modulator effects on neurotrophin expression
The Regents of the University of California 2010174*

• Piperidine derivatives useful for treating osteoporosis and osteoarthritis
AstraZeneca 2010175*

• Use of opioid antagonists to attenuate endothelial cell proliferation and migration
The University of Chicago 2010176*

• Combination histamine H1R and H4R antagonist therapy for treating pruritus
Janssen Pharmaceutica 2010177*

• Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
Merck 2010178*

• IL-8 receptor antagonists
SmithKline Beecham 2010180*

• Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
Rigel Pharmaceuticals 2010181*

• Use of C-SRC inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukaemia
Novartis 2010182*

• Process for synthesising 7-alkynyl-4-aminoquinazolines and a related intermediate
Aveo Pharmaceuticals 2010183*

• Implants for the treatment of dopamine associated states
Nupathe; The Trustees of the University of Pennsylvania 2010184*

• Dihydrothiopyrimidine for treating inflammatory disorders
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2010185*

• Haloaryl substituted aminopurines, compsns thereof, and methods of treatment therewith
Signal Pharmaceuticals 2010186*

• Compounds for diseases and disorders
Myriad Genetics 2010187*

• Chromium complexes
Mandrillus Pharma 2010188*

• Osmotic drug delivery system comprising release enhancing agent
Supermus Pharmaceuticals 2010189*

• Pharmaceutical solution formulations for pressurised metered dose inhalers
Chiesi Farmaceutici 2010190*

• Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
Gem Pharmaceuticals 2010191*